CYP19A1 and breast carcinoma: Genistein increases aromatase activity in ovarian, breast, and estrogen-dependent breast cancer cells, and may nullify the effects of anti-aromatase drugs in these cells, which should be taken into consideration in patients taking tamoxifen [103,104].